This Is An Image Of The Structural Formula For Amlodipine Besylate. (Amlodusp 1)
Amlodipine Besylate
Product Images NDC 50090-1021
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate (NDC 50090-1021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo)
This document seems to represent an analysis of some clinical trial. The trial probably involved a drug called Amlodipine. The document may present a time-to-event analysis in which an event rate of 0.0 is likely reported. Based on the P-value of 0.003 and Hazard Ratio of 0.691, it may be inferred that the treatment with Amlodipine had some impact on the event rate as compared to the control or placebo group. However, based on these values, it is unclear whether the effect was significant or not. Additionally, the table with the numbers and the "atrisk" notation suggest that there were some dropouts or censoring at different follow-up times. Overall, without more details, it is challenging to provide more specific and reliable information about this document.*
Figure 2 (Effects on Primary Endpoint of Amlodipine versus Placebo across Sub-Groups)
This table displays the results of a clinical trial comparing the effect of Amlodipine versus Placebo. The table shows the number of patients in different age groups and gender who have been administered either Amlodipine or Placebo treatment. Patients have also been divided based on their baseline sitting systolic blood pressure (SBP) and whether they have any existing vessel disease. Additionally, patients have been divided based on whether they underwent PCI-stent placement or not. The table also displays the hazard ratio with a 95% confidence interval, indicating the efficacy of Amlodipine vs Placebo.*
Label Image (Lbl500901020)
Label Image (Lbl500901021)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
